Formulary
Balsalazide sodium: Indications, Dosing, Side Effects and Interactions
Balsalazide sodium clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Balsalazide sodium: Indications, Dosing, Side Effects and Interactions
Balsalazide sodium clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Treatment of mild to moderate ulcerative colitis, acute attack**
- **Adult** (By Mouth): 2.25 g 3 times a day until remission occurs or for up to maximum of 12 weeks.
**Maintenance of remission of ulcerative colitis**
- **Adult** (By Mouth): 1.5 g twice daily (max. per dose 3 g), adjusted according to response; maximum 6 g per day.
**Treatment of mild to moderate ulcerative colitis, acute attack for balsalazide sodium**
- **Child 12-17 years** (By mouth): 2.25 g 3 times a day until remission occurs or for up to maximum of 12 weeks.
**Maintenance of remission of ulcerative colitis for balsalazide sodium**
- **Child 12-17 years** (By mouth): 1.5 g twice daily (max. per dose 3 g), adjusted according to response; maximum 6 g per day.
Cautions
History of asthma
Side effects
Common or very common Arthralgia; cough; diarrhoea; dizziness; fever; gastrointestinal discomfort; headache; leucopenia; myalgia; nausea; proteinuria; skin reactions; vomiting Uncommon Alopecia; depression; dyspnoea; face oedema; pancreatitis; paraesthesia; photosensitivity reaction; tachycardia; thrombocytopenia; vertigo Rare or very rare Agranulocytosis; angioedema; blood disorder; bone marrow disorders; cardiac inflammation; hepatic disorders; interstitial lung disease; lupus-like syndrome; nephritis tubulointerstitial; nephrotic syndrome; neutropenia; peripheral neuropathy; renal impairment; respiratory disorders Frequency not known Cholelithiasis; eosinophilia; haematuria; haemolytic anaemia; oligozoospermia (reversible); severe cutaneous adverse reactions (SCARs); ulcerative colitis aggravated Side-effects, further information A blood count should be performed and the drug stopped immediately if there is suspicion of a blood dyscrasia.
Pregnancy
Manufacturer advises avoid.
Breast feeding
Diarrhoea may develop in the infant. Monitoring in breast feeding Monitor breast-fed infants for diarrhoea.
Hepatic impairment
Manufacturer advises caution; avoid in severe impairment (no information available).
Renal impairment
Use with caution in mild impairment; avoid in moderate to severe impairment. M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Balsalazide sodium in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

